Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013

 Celsion Corporation to Hold First Quarter 2013 Financial Results Conference
                        Call on Thursday, May 9, 2013

PR Newswire

LAWRENCEVILLE, N.J., May 1, 2013

LAWRENCEVILLE, N.J., May 1, 2013 /PRNewswire/ --Celsion Corporation (NASDAQ:
CLSN), a leading oncology drug development company, today announced that it
would hold a conference call to discuss first quarter 2013 results at 11:00
a.m. EDT on Thursday, May 9, 2013. To participate in the call, interested
parties may dial 1-888-329-8862(Toll-Free/North America) or 1-719-325-2376
(International/Toll) and ask for The Celsion Corporation First Quarter 2013
Financial Results Conference Call to register ten minutes before the call is
scheduled to begin. The call will also be broadcast live on the internet at

The call will be archived for replay on Thursday, May 9, 2013 at 2:00p.m. EDT
and will remain available until Thursday, May 23, 2013. The replay can be
accessed at 1-877-870-5176(Toll-Free/North America) or 1-858-384-5517
(International/Toll) using Conference ID: 2227568. An audio replay of the
call will also be available on the Company's website, http://www.celsion.com,
for 30 days after 2:00 p.m. EDT on Thursday, May 9, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and
commercialization of innovative cancer drugs, including tumor-targeting
treatments using focused heat energy in combination with heat-activated
liposomal drug technology. Celsion has research, license, or commercialization
agreements with leading institutions such as the National Institutes of
Health, Duke University Medical Center, University of Hong Kong, the
University of Pisa, the UCLA Department of Medicine, the Kyungpook National
University Hospital, the Beijing Cancer Hospital and the University of
Oxford. For more information on Celsion, visit our website:

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in the Company's periodic reports filed with the Securities and Exchange
Commission. Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent events,
new information or otherwise.

Investor Contact

Jeffrey W. Church
Sr. Vice President – Corporate Strategy &
Investor Relations

SOURCE Celsion Corporation

Website: http://www.celsion.com
Press spacebar to pause and continue. Press esc to stop.